Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
|Podcasts|December 14, 2022
The Cutaneous Connection: JAK Inhibitor Safety for Treating AD
Author(s)Kaitlyn Bader, Associate Editor
In this episode, Christopher Bunick, MD, PhD, discusses a paper he recently co-authored, which explores JAK inhibitor safety compared to traditional systemic therapies for atopic dermatitis.
Advertisement
Advertisement
Related to this article
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
3
Dupilumab and Catch-Up Growth in Children With Severe Atopic Dermatitis
4
Improving Early Identification and Escalation of HS
5